Every route · Ankylosing spondylitis · Immune system, transplant and skin

Xeljanz for Ankylosing spondylitis: every route to paying for it

6 of 6 routes have a dated fact in our data for Xeljanz and Ankylosing spondylitis. Where we found nothing the page says so; that does not mean none exists.

The order is fixed and is not a ranking. The FDA label first, then public Medicare facts, then the manufacturer, then charities, then research access. It does not say which route is best for you, and no saving is computed.

A copy for a patient, a clinic or a pharmacist, with each source and the date we read it.

The routes, in order

1
Why this drug and this condition are paired
Active ankylosing spondylitis (AS), who have had an inadequate response or intolerance to one or more TNF blockers.
From the Indications and Usage text of the drug's FDA label. A label naming a condition is not a statement that the drug is approved, effective or covered for you.
Label on openFDA, read 2026-11-10 · receipt
2
Medicare Part D: the yearly out-of-pocket threshold
Found in our data
CMS prints the Part D out-of-pocket threshold as $2,400 in 2027 ($2,100 in 2026).
A benefit parameter of the standard Part D benefit. It applies to covered drugs under plan rules and is not a prediction of what you will pay. Your plan's formulary decides whether this drug is covered: check a formulary.
CMS Table V-2, read 2026-11-08
3
Medicare negotiated price
Found in our data
CMS has selected this drug for prices effective 2028-01-01. No price is published yet.
CMS negotiated prices, read 2026-11-06
4
Manufacturer and foundation programs
Found in our data
- Pfizer RxPathways receipt no new patients starting July 1, 2026 Limited the program's own page, read 2026-11-07
- RA Medication Assistance (Multiple Programs) status not recorded
A status is what the program's page says about taking applications, not whether you qualify. Each program has its own eligibility rules.
5
Charitable funds for Ankylosing spondylitis
Found in our data
We hold 1 fund for Ankylosing spondylitis: 0 open and 1 not open, read 2026-11-08.
Every fund, with its award level, insurance supported and source, is on the Ankylosing spondylitis page. A fund pays for a condition's costs, not necessarily this drug.
6
Clinical trial access
Found in our data
ClinicalTrials.gov lists 28 recruiting interventional trials that name this ingredient (read 2026-11-07).
A trial is research, not treatment access for everyone, and a listing is not a recommendation.
ClinicalTrials.gov, read 2026-11-07 · receipt

More about Xeljanz and Ankylosing spondylitis

Edition 2026-11, root 006ab9a329709cbe. See the licence page.

Questions

Is Xeljanz approved for Ankylosing spondylitis?

This page cannot say that. The Indications and Usage text of the drug's FDA label names Ankylosing spondylitis, which is the evidence for pairing them. Read the label and ask your prescriber.

What are the routes on this page?

Why this drug and this condition are paired; Medicare Part D: the yearly out-of-pocket threshold; Medicare negotiated price; Manufacturer and foundation programs; Charitable funds for Ankylosing spondylitis; Clinical trial access. For this drug and condition we found why this drug and this condition are paired, medicare part d: the yearly out-of-pocket threshold, medicare negotiated price, manufacturer and foundation programs, charitable funds for ankylosing spondylitis, clinical trial access.

Is the order a ranking?

No. The order is fixed: the label, then public Medicare facts, then the manufacturer, then charities, then research access. It does not say which route is best or cheapest for you, and no saving is computed.

How current is this?

Each route shows the date we read its source. Statuses are what the source said on that date.